ClinicalTrials.gg
RecruitingNCT01451502Updated Oct 6, 2026

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

An interventional study of Umbilical Cord Blood (UCB) in Lymphatic Diseases and Hematopoietic Malignancy, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Masonic Cancer Center, University of Minnesota · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2011; still recruiting 15 years 1 month later.
Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Lymphatic Diseases with a site in United States — 8 open to participants now, 17 under way, 1 of them phase 3. Lymphatic Diseases · United States.

Planned enrollment
8th of 42
250 · median 48
Started
2011
with 2 others
No phase
7 of 53
1 open now
Primary completion
2027-01
later than 7 of 16 live
Registered
19th of 53
by date

Among the 53 studies in Lymphatic Diseases with a site in United States, this one is the 8th largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2011, is one of 7 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 19th registered.

Lymphatic Diseases

83 studies on the registry are indexed under Lymphatic Diseases; 12 are open to participants now.

Browse Lymphatic Diseases studies →

Open to participants now

8 of the 53 studies in Lymphatic Diseases with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Lymphatic Diseases studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Lymphatic Diseases with a site in United States, or all of them as a file.
02

Study summary

For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.

Read the detailed description

Patients will receive intravenous hydration, acetaminophen and diphenhydramine hydrochloride (or appropriate alternative regimen) approximately 30 minutes prior to UCB infusion with doses adjusted for subject age and weight unless otherwise specified in the specific treatment protocol. Additional treatments will vary with the specific use of the UCB cells as specified in institutional review board (IRB)-approved disease-specific protocols at the University of Minnesota.

03

Conditions studied

  • Lymphatic Diseases
  • Hematopoietic Malignancy

Keywords

  • umbilical cord blood
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for an unlicensed umbilical cord blood (UCB) unit, the subject must meet each of the eligibility criteria listed below:

  • Subjects with any diagnosis for which there is an institutional review board (IRB) approved treatment protocol that requires UCB as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution after myeloablative or non myeloablative conditioning.
  • Subject (or parent/guardian) must provide written for the use of unlicensed UCB units with co-enrollment onto a University of Minnesota IRB-approved clinical trial that details the disease specific treatment plan that prescribes the use of UCB as source of cells
  • Subject has an unlicensed UCB unit that meets required cell dose and HLA matching criteria (as defined in the primary treatment protocol) that is considered negative for tested blood-borne pathogens and also lack an 'equivalent', licensed UCB unit from a University of Minnesota approved Cord Blood Bank

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria are specified in the treatment protocol according to indication.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Unlicensed Umbilical Cord Blood Infusion

    All patients will be registered in OnCore under this protocol as well as the specific treatment protocol. * Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride * Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines. * Infusion of minimally manipulated unlicensed UCB units: * vital signs Monitoring during and after UCB infusion: * Management of infusion reactions * Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines.

    Biological: Umbilical Cord Blood (UCB)

Interventions

  • BiologicalCord bloodStudies of Cord bloodCord blood pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Incidence of Blood Borne Pathogen Transmission from Unlicensed UCB Units.

    Documentation of events for the purpose of this study will only be for those events at least possibly related to the unlicensed UCB. Monitoring for acute infusional toxicities will end 24 hours after the umbilical cord blood (UCB) infusion.

    Time frame: Within 24 Hours Post Infusion

Secondary outcomes

  1. Incidence of Serious Infusion Reactions of Minimally Manipulated Unlicensed UCB Units

    point estimations and 95% confidence intervals of serious infusion reaction

    Time frame: Up to Day 180

  2. Number of the Desired Lineage Specific Cells in Minimally Manipulated Unlicensed UCB Units

    Upon thawing (e.g., number of CD34 and colony forming cells for hematopoietic products or number of CD4+/CD25+/CD127- cells for Treg products prior to further manipulation).

    Time frame: Prior to Infusion

  3. Incidence of Mislabeled UCB Units

    Point estimations and 95% confidence intervals of incidences mislabeled UCB units

    Time frame: Up to Day 180

  4. Comparison of Specific Cord Blood Banks (CBBs)

    Determine if bacterial contamination, poor cell recoveries, shipment of mislabeled units, blood borne pathogen transmission or serious infusion reactions are more prevalent in units from specific CBBs.

    Time frame: Up to Day 180

07

Study locations

1 of 1 sites recruiting
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Claudio Brunstein, MD · Contactbruns072@umn.edu · 612-625-3918
    • Claudio Brunstein, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2011 (actual). Primary completion is estimated for Jan 2027, 183 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Jan 2027 and completion Feb 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Oct 13, 2011
StartActual
Oct 20, 2011
Primary completionEst.
Jan 2027was Sep 2026
CompletionEst.
Feb 2028was Feb 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jan 2027
Oct 6, 2026
Study completion
Feb 2027→Feb 2028
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 2026→Jan 2027
    Study completion Feb 2027→Feb 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01451502
Responsible party
Sponsor
First posted
Oct 13, 2011
Start date
Oct 20, 2011
Primary completion
Jan 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Alex Hoover, MD, MSc
principal investigator · Masonic Cancer Center, University of Minnesota

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cord blood

Start the discussion